Fervid research has uncovered dozens of antibodies that shield cells from HIV. These broadly neutralizing antibodies (bNAbs) protect monkeys from SHIV, the simian-HIV hybrid. Thousand-person human trials are already dripping bNAbs into high-risk men and women to see if they prevent HIV infection. And much ...

A team led by UCL researchers has identified how HIV is able to infect macrophages, a type of white blood cell integral to the immune system, despite the presence of a protective protein. They discovered a treatment that can maintain macrophage defences which could be ...

Without antiretroviral drug treatment, the majority of people infected with HIV ultimately develop AIDS, as the virus changes and evolves beyond the body’s ability to control it. But a small group of infected individuals—called elite controllers—possess immune systems capable of defeating the virus. They accomplish ...

Around one in six young and middle-aged HIV-positive men doing well on antiretroviral therapy (ART) had low testosterone levels, French investigators report in the online edition of AIDS. Overall, 12% of the sample had low testosterone, or male hypogonadism. Risk factors were longer duration of ...

Gene therapy — which involves modifying genetic material, such as DNA and RNA — holds exciting potential as a cure for numerous diseases and conditions, including HIV. Timothy Brown (the “Berlin patient”) remains the only person known to have been cured of HIV. Brown received a ...

A group of researchers is investigating whether or not interferon-free therapy could reverse the cognitive declines that appear to accompany infection with the hepatitis C virus (HCV), with or HIV coinfection. Felix Kleefeld, of Berlin, Germany, and colleagues examined how eradicating HCV affected the cognition of ...

A pioneering new clinical trial aiming to find a radically improved course of treatment for drug-resistant tuberculosis (TB) began on 17th January 2017, when the first patient took the first pill in Uzbekistan. The phase II/III trial, called TB PRACTECAL, aims to find a treatment regime ...

Researchers in two new studies say they can leverage the body’s own antibodies to fight the virus that causes AIDS. In the field of HIV research, antibodies continue to be a targeted area. Two new studies published January 19 in Science Translational Medicine offer potential new treatment ...

For the first time in the United States, a 31-year-old male with primary sclerosing cholangitis received a liver transplant from a deceased donor infected with hepatitis C virus (HCV). Primary sclerosis cholangitis slowly damages the bile ducts in the liver. After Lorenzo Swank learned his liver ...

Agonist therapy with methadone could use existing structure to reduce addiction, HIV Opioid agonist therapy using methadone is regarded as one of the most effective treatments for opioid use disorders as well as helping to reduce HIV risks. Such therapy, however, is not yet available in ...

GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing human vaccines, announced today (January 23) the initiation of the next human clinical trial of GeoVax’s preventive HIV vaccine, GOVX-B11. The Phase 1 trial (designated HVTN 114) is being conducted by the HIV Vaccine Trials Network ...

Kaiser Family Foundation: The Global HIV/AIDS Epidemic This updated fact sheet provides information on current HIV prevalence and incidence, prevention and treatment strategies, and the U.S. and global responses to the epidemic (1/19). Kaiser Family Foundation: The U.S. President’s Emergency Plan for AIDS Relief (PEPFAR) This updated fact ...

Long-term care for an aging HIV population is uncharted territory, as researchers and physicians are seeing the effects of the first wave of individuals who have been on antiretroviral therapy (ART) for a significant period of time. An increasing amount of academic and clinical research has ...

Targeting chronic hepatitis B infections affecting more than 240 million people worldwide GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing human vaccines, announced today (January 17) that it has entered into a research collaboration agreement with Georgia State University Research Foundation (GSU) to advance the ...

Researchers at University of California San Diego School of Medicine, with colleagues at the National Institute of Diabetes and Digestive and Kidney Diseases, the University of Manitoba and St. Boniface Hospital Albrechtsen Research Centre in Canada, have identified a molecular signaling pathway that, when blocked, ...

DPP® HIV-Syphilis Assay on track for U.S. regulatory submission in 2017 MEDFORD, N.Y., Jan. 17, 2017 — Chembio Diagnostics, Inc. (Nasdaq:CEMI), a leader in point-of-care (POC) diagnostic tests for infectious diseases, today announced that it has received a CE mark for its DPP® HIV-Syphilis combination assay. ...

Even in very early (acute) HIV infection—before fourth generation HIV test assays are able to detect an HIV infection—immune activation and inflammatory processes may already be occurring, new research shows. And, very early antiretroviral therapy (ART) may reduce, although not fully suppress, production of inflammatory markers ...

A research team led by investigators of the Rockefeller University in New York and Prof Florian Klein, University Hospital Cologne and German Center for Infection Research (DZIF), has tested a new HIV neutralising antibody, called 10-1074, in humans. The results of the trial have just ...